TrialGynecologic oncology2017

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

John K Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.